Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases - Takeaways - MDSpire
From the Journals

Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases

In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intrave...

  • By

  • Matthew Stenger

  • May 5, 2026

  • 3 min

Share

  • 1

    Phase II trial PACHA-01 focused on oxaliplatin for colorectal liver metastases.

  • 2

    Median hepatic recurrence-free survival increased to 25 months with hepatic arterial infusion.

  • 3

    IV group showed a median of 12 months recurrence-free survival.

  • 4

    81% of hepatic arterial infusion patients received four or more chemotherapy cycles.

  • 5

    Grade 3 to 4 adverse events were more common in the arterial infusion group (58%).

  • 6

    Findings support future phase III trials.

Original Source(s)

Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases

  • by Matthew Stenger

  • May 5, 2026

Related Content

Roving Reporter Asks: Where Do You See the Most Progress in CGT Manufacturing and Scalability?

IBTV speaks with industry leaders at the 2025 Meeting on the Mesa to explore advances in scaling cell and gene therapies

  • May 6, 2026

  • 1 min
Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer

Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients w...

Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL

In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL).